stockrowNeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +72.1%
- Free cash flow
- −3,724.2%
- Total debt
- +10.9%
Quarter to September 2026, against a year earlier
Follow NEO
Alert me
NeoGenomics, Inc. (NEO) Revenue
NeoGenomics, Inc.'s revenue for fiscal 2025 was $727.3M, up 10.1% from $660.6M in fiscal 2024. Over the twelve months to 30 September 2026 it was $787.8M. Over the past ten years it has ranged from $99.8M (fiscal 2015) to $727.3M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 10 consecutive fiscal years. NeoGenomics, Inc. ranks 21st of 47 Diagnostics & Research companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $727.3M | 10.11% |
| FY2024 | $660.6M | 11.65% |
| FY2023 | $591.6M | 16.07% |
| FY2022 | $509.7M | 5.24% |
| FY2021 | $484.3M | 8.97% |
| FY2020 | $444.4M | 8.71% |
| FY2019 | $408.8M | 47.73% |
| FY2018 | $276.7M | 15.19% |
| FY2017 | $240.3M | 3.64% |
| FY2016 | $231.8M | 132.27% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $209.3M | 3.77% |
| Jun 2026 | $201.7M | 8.03% |
| Mar 2026 | $186.7M | (1.84%) |
| Dec 2025 | $190.2M | 1.26% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| NEO NeoGenomics, Inc. | $787.8M |
| VCYT Veracyte, Inc. compare | $581.8M |
| OPK OPKO Health, Inc. compare | $501.6M |
| CDNA CareDx, Inc. compare | $497.4M |
| WGS GeneDx Holdings Corp. compare | $454.4M |
| CSTL Castle Biosciences, Inc. compare | $377.1M |
| ADPT Adaptive Biotechnologies Corporation compare | $298.0M |
| PSNL Personalis, Inc. compare | $80.8M |
| FRNM Freenome, Inc compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on NEO
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement